The median duration of response on erdafitinib among patients with FGFR fusions or mutations in the NCI-MATCH was <6 months. This may in part be due to low dependency on FGFR signaling in the genetic ...

A new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has identified a ...

Investigators also confirmed that FGFR2 fusion–positive tumors have a higher expression of FGFR2 but were not associated with higher expression of FGFR1, FGFR3, or FGFR4. Investigators concluded that ...

A phase Ib/II, open-label, dose escalation study to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer. Background: FGFR inhibition is a promising and ...

Development of FGFR inhibitors, which target fibroblast growth factor receptors, is among the most important advances in the treatment of cholangiocarcinoma. The FDA has accepted Taiho Oncology’s ...

Genetic alterations in some fibroblast growth factor receptor (FGFR) genes have been associated with bladder cancers, and as many as one-third of urothelial cancers show aberrations in FGFR family ...

A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular bone repair in mouse models of osteochondrodysplasia, a group of genetic ...

What if the brain's response to stress could be read not in fleeting neurotransmitter bursts, but in the quieting of genes ...